Ikena Oncology Inc (NAS:IKNA)

$ 1.57 0.04 (2.61%) Market Cap: 75.77 Mil Enterprise Value: -55.80 Mil PE Ratio: 0 PB Ratio: 0.56 GF Score: 33/100

Ikena Oncology Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Ikena Oncology Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 25, 2023
Ikena Oncology Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Ikena Oncology Inc at Stifel Healthcare Conference (Virtual) Transcript
Nov 15, 2021
Ikena Oncology Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021

Ikena Oncology Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 04:30PM GMT

Release Date Price: $6.79 (-2.02%)

Transcript

Mark Manfredi

Ikena Oncology, Inc - President & CEO

Thanks for the invitation to present on Ikena. I'm assuming I can drive the slides.

So we are a targeted oncology company. We're clinical stage, and we work on two different pathways. One is a pathway that is a first-in-class opportunity. It's a quite new pathway in terms of drug discovery and drug development. But it's been around for a long time in terms of its role in oncogenesis and driving tumors.

And most excitingly, there's been some proof of concept in the pathway recently at the ACR showing that an inhibitor to the Hippo pathway shows clinical activity in mesothelioma. And I'll talk you through that rationale for that indication, as well as how we're different with our approach in terms of that pathway.

And the other pathway is well known as the RAS pathway. Obviously, there's a lot of excitement in this pathway. But if you look at what is currently addressed by current therapies, even with the emergence of RAS-specific therapies, there's just a tremendous amount of unmet need. And there's about 20% to 25% of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.